• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

布鲁顿酪氨酸激酶(BTK)可阻断小鼠双微体2(MDM2)对p53活性的抑制作用。

BTK blocks the inhibitory effects of MDM2 on p53 activity.

作者信息

Rada Miran, Althubiti Mohammad, Ekpenyong-Akiba Akang E, Lee Koon-Guan, Lam Kong Peng, Fedorova Olga, Barlev Nickolai A, Macip Salvador

机构信息

Department of Molecular and Cell Biology, Mechanisms of Cancer and Aging Laboratory, University of Leicester, Leicester, UK.

Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Mecca, Saudi Arabia.

出版信息

Oncotarget. 2017 Nov 20;8(63):106639-106647. doi: 10.18632/oncotarget.22543. eCollection 2017 Dec 5.

DOI:10.18632/oncotarget.22543
PMID:29290977
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5739762/
Abstract

p53 is a tumour suppressor that is activated in response to various types of stress. It is regulated by a complex pattern of over 50 different post-translational modifications, including ubiquitination by the E3 ligase MDM2, which leads to its proteasomal degradation. We have previously reported that expression of Bruton's Tyrosine Kinase (BTK) induces phosphorylation of p53 at the N-terminus, including Serine 15, and increases its protein levels and activity. The mechanisms involved in this process are not completely understood. Here, we show that BTK also increases MDM2 and is necessary for MDM2 upregulation after DNA damage, consistent with what we have shown for other p53 target genes. Moreover, we found that BTK binds to MDM2 on its PH domain and induces its phosphorylation. This suggested a negative regulation of MDM2 functions by BTK, supported by the fact BTK expression rescued the inhibitory effects of MDM2 on p53 transcriptional activity. Indeed, we observed that BTK mediated the loss of the ubiquitination activity of MDM2, a process that was dependent on the phosphorylation functions of BTK. Our data together shows that the kinase activity of BTK plays an important role in disrupting the MDM2-p53 negative feedback loop by acting at different levels, including binding to and inactivation of MDM2. This study provides a potential mechanism to explain how BTK modulates p53 functions.

摘要

p53是一种肿瘤抑制因子,可在应对各种类型的应激时被激活。它受50多种不同翻译后修饰的复杂模式调控,包括E3连接酶MDM2介导的泛素化,这会导致其经蛋白酶体降解。我们之前报道过,布鲁顿酪氨酸激酶(BTK)的表达会诱导p53在N端(包括丝氨酸15)磷酸化,并增加其蛋白水平和活性。这一过程所涉及的机制尚未完全明确。在此,我们表明BTK还会增加MDM2的表达,并且在DNA损伤后对MDM2的上调是必需的,这与我们在其他p53靶基因上的研究结果一致。此外,我们发现BTK在其PH结构域与MDM2结合并诱导其磷酸化。这表明BTK对MDM2的功能具有负调控作用,BTK表达挽救了MDM2对p53转录活性的抑制作用这一事实也支持了这一点。实际上,我们观察到BTK介导了MDM2泛素化活性的丧失,这一过程依赖于BTK的磷酸化功能。我们的数据共同表明,BTK的激酶活性通过在不同层面发挥作用,包括与MDM2结合并使其失活,在破坏MDM2-p53负反馈环中发挥重要作用。这项研究提供了一种潜在机制来解释BTK如何调节p53的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/a13c74539257/oncotarget-08-106639-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/d1dd245517b7/oncotarget-08-106639-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/112d7eaaa4da/oncotarget-08-106639-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/6d2d7218dcf7/oncotarget-08-106639-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/a13c74539257/oncotarget-08-106639-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/d1dd245517b7/oncotarget-08-106639-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/112d7eaaa4da/oncotarget-08-106639-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/6d2d7218dcf7/oncotarget-08-106639-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608e/5739762/a13c74539257/oncotarget-08-106639-g004.jpg

相似文献

1
BTK blocks the inhibitory effects of MDM2 on p53 activity.布鲁顿酪氨酸激酶(BTK)可阻断小鼠双微体2(MDM2)对p53活性的抑制作用。
Oncotarget. 2017 Nov 20;8(63):106639-106647. doi: 10.18632/oncotarget.22543. eCollection 2017 Dec 5.
2
BTK modulates p73 activity to induce apoptosis independently of p53.布鲁顿酪氨酸激酶(BTK)调节p73活性以独立于p53诱导细胞凋亡。
Cell Death Discov. 2018 Sep 11;4:30. doi: 10.1038/s41420-018-0097-7. eCollection 2018.
3
The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?多位点磷酸化调控 MDM2——基于分子的肿瘤靶向干预机会?
Semin Cancer Biol. 2010 Feb;20(1):19-28. doi: 10.1016/j.semcancer.2009.10.005. Epub 2009 Nov 6.
4
BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.BTK 调节 p53 活性以增强细胞凋亡和衰老反应。
Cancer Res. 2016 Sep 15;76(18):5405-14. doi: 10.1158/0008-5472.CAN-16-0690. Epub 2016 Jul 26.
5
Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.激活环磷酸化调节布鲁顿酪氨酸激酶(Btk)激酶结构域的活性。
Biochemistry. 2009 Mar 10;48(9):2021-32. doi: 10.1021/bi8019756.
6
Dual-site regulation of MDM2 E3-ubiquitin ligase activity.MDM2 E3泛素连接酶活性的双位点调控。
Mol Cell. 2006 Jul 21;23(2):251-63. doi: 10.1016/j.molcel.2006.05.029.
7
ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.DNA损伤后,ATM和Chk2依赖的MDMX磷酸化有助于p53激活。
EMBO J. 2005 Oct 5;24(19):3411-22. doi: 10.1038/sj.emboj.7600812. Epub 2005 Sep 15.
8
RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.RNF12通过靶向MDM2进行降解,促进p53依赖的细胞生长抑制和凋亡。
Cancer Lett. 2016 May 28;375(1):133-141. doi: 10.1016/j.canlet.2016.02.013. Epub 2016 Feb 27.
9
Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.p19(ARF)与Mdm2的结合抑制了Mdm2对肿瘤抑制因子p53的泛素连接酶活性。
EMBO J. 1999 Jan 4;18(1):22-7. doi: 10.1093/emboj/18.1.22.
10
The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.Wip1磷酸酶在p53-Mdm2自动调节环路中起把关作用。
Cancer Cell. 2007 Oct;12(4):342-54. doi: 10.1016/j.ccr.2007.08.033.

引用本文的文献

1
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications.癌症中的糖基化:机制、诊断标志物及治疗应用。
Mol Cell Biochem. 2025 May 19. doi: 10.1007/s11010-025-05303-1.
2
Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni syndrome- paving the path towards precision medicine: a case report.利用李-弗劳梅尼综合征患者的体细胞致癌驱动基因改变——迈向精准医学之路:一例病例报告
J Cancer Res Clin Oncol. 2025 Jan 16;151(1):37. doi: 10.1007/s00432-024-06077-7.
3
Cancer Cells Promote Phenotypic Alterations in Hepatocytes at the Edge of Cancer Cell Nests to Facilitate Vessel Co-Option Establishment in Colorectal Cancer Liver Metastases.

本文引用的文献

1
BTK Modulates p53 Activity to Enhance Apoptotic and Senescent Responses.BTK 调节 p53 活性以增强细胞凋亡和衰老反应。
Cancer Res. 2016 Sep 15;76(18):5405-14. doi: 10.1158/0008-5472.CAN-16-0690. Epub 2016 Jul 26.
2
Human EHMT2/G9a activates p53 through methylation-independent mechanism.人源 EHMT2/G9a 通过非甲基化依赖机制激活 p53。
Oncogene. 2017 Feb 16;36(7):922-932. doi: 10.1038/onc.2016.258. Epub 2016 Jul 25.
3
KMT Set7/9 affects genotoxic stress response via the Mdm2 axis.赖氨酸甲基转移酶Set7/9通过Mdm2轴影响基因毒性应激反应。
癌细胞促进癌细胞巢边缘肝细胞的表型改变,以促进结直肠癌肝转移中血管选择建立。
Cancers (Basel). 2022 Mar 4;14(5):1318. doi: 10.3390/cancers14051318.
4
Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival.Kinomics 平台使用 GBM 组织鉴定出 BTK 与更高的患者生存率相关。
Life Sci Alliance. 2021 Oct 13;4(12). doi: 10.26508/lsa.202101054. Print 2021 Dec.
5
Runt related transcription factor-1 plays a central role in vessel co-option of colorectal cancer liver metastases.Runt 相关转录因子-1 在结直肠癌肝转移血管生成中起核心作用。
Commun Biol. 2021 Aug 10;4(1):950. doi: 10.1038/s42003-021-02481-8.
6
The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.RNA 结合蛋白 HuR 是 Pirh2 E3 泛素连接酶的一个新靶点。
Cell Death Dis. 2021 Jun 5;12(6):581. doi: 10.1038/s41419-021-03871-w.
7
The roles and regulation of MDM2 and MDMX: it is not just about p53.MDM2 和 MDMX 的作用和调节:不仅仅是关于 p53。
Genes Dev. 2021 May 1;35(9-10):575-601. doi: 10.1101/gad.347872.120. Epub 2021 Apr 22.
8
Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer.14-3-3蛋白相互作用网络对p53的调控:癌症药物研发的新机遇
Cell Death Discov. 2020 Nov 16;6(1):126. doi: 10.1038/s41420-020-00362-3.
9
Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.脾脏酪氨酸激酶在多种癌症中的表达及其临床结果的系统分析
Saudi J Med Med Sci. 2020 May-Aug;8(2):95-104. doi: 10.4103/sjmms.sjmms_300_19. Epub 2020 Apr 17.
10
BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining.BTK有望成为肺腺癌的预后因素及肿瘤微环境重塑的指标:基于TCGA数据挖掘的研究
Front Oncol. 2020 Apr 15;10:424. doi: 10.3389/fonc.2020.00424. eCollection 2020.
Oncotarget. 2015 Sep 22;6(28):25843-55. doi: 10.18632/oncotarget.4584.
4
The 26S proteasome is a multifaceted target for anti-cancer therapies.26S蛋白酶体是抗癌疗法的一个多方面的靶点。
Oncotarget. 2015 Sep 22;6(28):24733-49. doi: 10.18632/oncotarget.4619.
5
The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.布鲁顿酪氨酸激酶抑制剂依鲁替尼联合化学免疫疗法治疗慢性淋巴细胞白血病患者。
Blood. 2015 May 7;125(19):2915-22. doi: 10.1182/blood-2014-09-585869. Epub 2015 Mar 9.
6
Bruton's tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response.布鲁顿酪氨酸激酶使DDX41磷酸化并激活其与双链DNA和STING的结合,从而启动1型干扰素反应。
Cell Rep. 2015 Feb 24;10(7):1055-65. doi: 10.1016/j.celrep.2015.01.039. Epub 2015 Feb 19.
7
Characterization of novel markers of senescence and their prognostic potential in cancer.衰老新标志物的特征及其在癌症中的预后潜力
Cell Death Dis. 2014 Nov 20;5(11):e1528. doi: 10.1038/cddis.2014.489.
8
KMTase Set7/9 is a critical regulator of E2F1 activity upon genotoxic stress.赖氨酸甲基转移酶Set7/9是基因毒性应激时E2F1活性的关键调节因子。
Cell Death Differ. 2014 Dec;21(12):1889-99. doi: 10.1038/cdd.2014.108. Epub 2014 Aug 15.
9
The role of the HIF-1α transcription factor in increased cell division at physiological oxygen tensions.低氧诱导因子-1α(HIF-1α)转录因子在生理氧张力下细胞分裂增加中的作用。
PLoS One. 2014 May 16;9(5):e97938. doi: 10.1371/journal.pone.0097938. eCollection 2014.
10
Targeting Bruton's tyrosine kinase in B cell malignancies.针对 B 细胞恶性肿瘤的布鲁顿酪氨酸激酶。
Nat Rev Cancer. 2014 Apr;14(4):219-32. doi: 10.1038/nrc3702.